Literature DB >> 21145719

Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD).

Emily S Wan1, Dawn L DeMeo, Craig P Hersh, Steven D Shapiro, Richard A Rosiello, Susan R Sama, Anne L Fuhlbrigge, Marilyn G Foreman, Edwin K Silverman.   

Abstract

BACKGROUND: Acute exacerbations are a significant source of morbidity and mortality associated with chronic obstructive pulmonary disease. Among individuals with COPD, some patients suffer an inordinate number of exacerbations while others remain relatively protected. We undertook a study to determine the clinical factors associated with "frequent exacerbator" status within a population of subjects with severe COPD.
METHODS: Case-control cohort recruited from two Boston-area practices. All subjects had GOLD stage 3 or 4 (FEV(1) ≤ 50% predicted) COPD. "Frequent exacerbators" (n = 192) had an average of ≥2 moderate-to-severe exacerbations per year while "non-exacerbators" (n = 153) had no exacerbations in the preceding 12 months. Multivariate logistic regression was performed to determine the significant clinical predictors of "frequent exacerbator" status.
RESULTS: Physician-diagnosed asthma was a significant predictor of frequent exacerbations. Within a subset of our cohort, the modified Medical Research Council dyspnea score and FEF (25-75%) predicted were also significant clinical predictors of frequent exacerbator status (p < 0.05). Differences in exacerbation frequency were not found to be due to increased current tobacco use or decreased rates of maintenance medication use.
CONCLUSIONS: Within our severe COPD cohort, a history of physician-diagnosed asthma was found to be a significant clinical predictor of frequent exacerbations. Although traditional risk factors such as decreased FEV(1)% predicted were not significantly associated with frequent exacerbator status, lower mid-expiratory flow rates, as assessed by FEF (25-75%) predicted, were significantly associated with frequent exacerbations in a subset of our cohort.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21145719      PMCID: PMC3046312          DOI: 10.1016/j.rmed.2010.11.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  49 in total

1.  Feasibility of spirometry and reversibility testing for the identification of patients with chronic obstructive pulmonary disease on asthma registers in general practice.

Authors:  C Griffiths; G Feder; J Wedzicha; G Foster; A Livingstone; G S Marlowe
Journal:  Respir Med       Date:  1999-12       Impact factor: 3.415

2.  Impact of preventing exacerbations on deterioration of health status in COPD.

Authors:  S Spencer; P M A Calverley; P S Burge; P W Jones
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

3.  The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

Authors:  F Andersson; S Borg; S A Jansson; A C Jonsson; A Ericsson; C Prütz; E Rönmark; B Lundbäck
Journal:  Respir Med       Date:  2002-09       Impact factor: 3.415

4.  Costs of chronic bronchitis and COPD: a 1-year follow-up study.

Authors:  Marc Miravitlles; Cristina Murio; Tina Guerrero; Ramon Gisbert
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

5.  Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD.

Authors:  Marc Miravitlles; Cristina Murio; Tina Guerrero; Ramon Gisbert
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

6.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  Peter Calverley; Romain Pauwels; Jørgen Vestbo; Paul Jones; Neil Pride; Amund Gulsvik; Julie Anderson; Claire Maden
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

7.  Pharmacoeconomic evaluation of COPD.

Authors:  D E Hilleman; N Dewan; M Malesker; M Friedman
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

8.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 9.  COPD exacerbations: definitions and classifications.

Authors:  S Burge; J A Wedzicha
Journal:  Eur Respir J Suppl       Date:  2003-06

10.  The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom.

Authors:  Joan B Soriano; Kourtney J Davis; Bobbie Coleman; George Visick; David Mannino; Neil B Pride
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

View more
  14 in total

1.  Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation.

Authors:  Jung-Wan Yoo; Yoonki Hong; Joon Beom Seo; Eun Jin Chae; Seung Won Ra; Ji-Hyun Lee; Eun Kyung Kim; Seunghee Baek; Tae-Hyung Kim; Woo Jin Kim; Jin Hwa Lee; Sang-Min Lee; Sangyeub Lee; Seong Yong Lim; Tae Rim Shin; Ho Il Yoon; Seung Soo Sheen; Jae Seung Lee; Jin Won Huh; Yeon-Mok Oh; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

2.  Significance of Medication History at the Time of Entry into the COPDGene Study: Relationship with Exacerbation and CT Metrics.

Authors:  Seoung Ju Park; Barry Make; Craig P Hersh; Russell P Bowler
Journal:  COPD       Date:  2015-08       Impact factor: 2.409

Review 3.  Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Authors:  Alvar Agustí; Peter M Calverley; Marc Decramer; Robert A Stockley; Jadwiga A Wedzicha
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

4.  Predicting Hospitalization Due to COPD Exacerbations in Swedish Primary Care Patients Using Machine Learning - Based on the ARCTIC Study.

Authors:  Björn Ställberg; Karin Lisspers; Kjell Larsson; Christer Janson; Mario Müller; Mateusz Łuczko; Bine Kjøller Bjerregaard; Gerald Bacher; Björn Holzhauer; Pankaj Goyal; Gunnar Johansson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-16

5.  Predictors of exacerbations of asthma and COPD during one year in primary care.

Authors:  Salwan Al-ani; Mark Spigt; Per Hofset; Hasse Melbye
Journal:  Fam Pract       Date:  2013-10-10       Impact factor: 2.267

6.  Severe COPD cases from Korea, Poland, and USA have substantial differences in respiratory symptoms and other respiratory illnesses.

Authors:  Woo Jin Kim; Jae-Joon Yim; Deog Kyeom Kim; Myung Goo Lee; Anne L Fuhlbrigge; Pawel Sliwinski; Iwona Hawrylkiewicz; Emily S Wan; Michael H Cho; Edwin K Silverman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-30

7.  Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations.

Authors:  Yusheng Cheng; Xiongwen Tu; Linlin Pan; Shuai Lu; Ming Xing; Linlin Li; Xingwu Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-07-18

8.  Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease.

Authors:  Loes C M Bertens; Johannes B Reitsma; Karel G M Moons; Yvonne van Mourik; Jan Willem J Lammers; Berna D L Broekhuizen; Arno W Hoes; Frans H Rutten
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-10

9.  Is 'GOLD' standard for the management of COPD in clinical practice?

Authors:  Barbara P Yawn
Journal:  Drugs Context       Date:  2012-11-26

10.  Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.

Authors:  Peter M Calverley; Dirkje S Postma; Antonio R Anzueto; Barry J Make; Göran Eriksson; Stefan Peterson; Christine R Jenkins
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.